# Navigating Breastfeeding in the Context of Substance and Opioid Use Disorders

Michelle A. Cabán-Ruiz, Ph.D. (she/her/hers) – Addiction Researcher Angélica M. Fuentes-Armesto, MD, DABFM (she/her/hers) – Addiction Medicine Fellow Henry X. Nieves-Díaz, MD, DABFM (he/him/his) – Addiction Medicine Fellow

Universidad Central del Caribe - Bayamón, Puerto Rico

Presented at ASAM's 56th Annual Conference Saturday, April 26, 2025



## **Disclosure Information**

Navigating Breastfeeding in the Context of Substance and Opioid Use Disorders

Saturday, April 26, 2025 10:30 AM – 11:45 AM

Michelle A. Cabán-Ruiz, Ph.D. (she/her/hers)

Clinical Psychologist and Addiction Researcher Universidad Central del Caribe

No disclosures





## **Disclosure Information**

Navigating Breastfeeding in the Context of Substance and Opioid Use Disorders

Saturday, April 26, 2025 10:30 AM – 11:45 AM

Angélica M. Fuentes-Armesto M.D, DABFM (she/her/hers)

Addiction Medicine Fellow Universidad Central del Caribe

No disclosures





## **Disclosure Information**

Navigating Breastfeeding in the Context of Substance and Opioid Use Disorders

Saturday, April 26, 2025 10:30 AM – 11:45 AM

Henry X. Nieves-Díaz, M.D, DABFM (he/him/his)

Addiction Medicine Fellow Universidad Central del Caribe

No disclosures





## **Learning Objectives**

(1)

Review and discuss current statistics on breastfeeding and substance use disorders

2

Discuss research findings from our study: Substance use in Puerto Rican breastfeeding persons 3

Equip professiona Is with clinical tools to navigate breastfeeding in patients with substance use disorders (SUD). 4

Discuss evidencebased recommendations and updated protocols (ABM Protocol 21, ASAM, SAMHSA).





# Literature review



#### **General Overview of Substance Use Disorders (SUD)**

#### How Are Diseases Classified?









The DSM-5 and ICD-11 are two of the most respected medical manuals in the world for classifying diseases & disorders

- SUDs involve patterns of substance use that cause harm, impairment, or distress (APA, 2013).
- They are linked with various issues in physical, mental, social, and legal domains.
- Diagnosed using two main classification systems:
  - ICD-11 (World Health Organization).
  - DSM-5-TR (American Psychiatric Association).



#### **Global Prevalence of Substance Use**

- Alcohol is the most consumed substance worldwide (2.3 billion users, ~40% of adults) (WHO, 2018).
- Tobacco use has declined but still has 1.1 billion global users (Reitsma et al., 2021).
- Cannabis is the most commonly used illicit drug (200 million users) and involved in more than half of global drug offenses (United Nations Office on Drugs and Crime, 2022).
- Opioids cause the highest number of drug-related deaths, increasing by 41% over the past decade (Volkow & Blanco, 2023).



#### **Demographic Trends and Gender Disparities**

- SUD rates vary by country, socioeconomic status, and specific substances (Degenhardt et al., 2018).
- Historically, SUD was more prevalent in males, but recent trends show a faster rise among females (Grant et al., 2017).
- Alcohol use disorder (AUD) in females increased by 84%, compared to 35% in males (Verplaetse et al., 2021).
- This highlights the urgent need for research into gender and sex disparities in SUD (Cornish & Prasad, 2021).



Degenhardt, L., Charlson, F., Ferrari, A., Santomauro, D., Erskine, H., Mantilla-Herrara, A., ... & Vos, T. (2018). The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *The Lancet Psychiatry*, 5(12), 987-1012.

Grant, B. F., Chou, S. P., Saha, T. D., Pickering, R. P., Kerridge, B. T., Ruan, W. J., ... & Hasin, D. S. (2017). Prevalence of 12-month alcohol use, high-risk drinking, and DSM-IV alcohol use disorder in the United States, 2001–2002 to 2012–2013: results from the National Epidemiologic Survey on Alcohol and Related Conditions. JAMA psychiatry, 74(9), 911–923.

#### **Substance Use During Pregnancy and Breastfeeding**

- Marijuana is the most commonly used illicit drug during pregnancy, followed by prescription opioids (Center for Behavioral Health Statistics and Quality, 2016).
- SUD is less prevalent in pregnant individuals compared to non-pregnant individuals:
  - 3.6% qualify for Alcohol Use Disorder (AUD).
  - 1.6% meet criteria for a Drug Use Disorder (DUD) (Vesga-Lopez et al., 2008).
- Pre-pregnancy substance use is a strong predictor of prenatal use (Harrison & Sidebottom, 2009; Ward et al., 2006; McHugh et al., 2018).



#### **Substance Use During Pregnancy and Breastfeeding**





Opioid-affected births have quadrupled over the last decade, to 6.5/1,000 deliveries.





Methamphetamineaffected births have also increased over the last decade, to 2.4/1,000 deliveries.





Opioid use in pregnancy increases the **risk of maternal death and life- threatening health issues** by 50%, and meth use increases these risks by 150%.



#### **Substance Use During Pregnancy and Breastfeeding**





SUDs are increasing among all groups of childbearing persons but the largest increases were reported in rural communities, lowincome communities, and those with Medicaid coverage for their pregnancy care.





People of color have greater risk for life-threatening health issues compared to white people when their pregnancies are complicated by SUD and other behavioral health conditions.





Substance-affected deliveries result in increased healthcare costs. Neonatal abstinence syndrome, a group of problems that can affect infants exposed to opioids in the womb, accounted for \$3 billion in hospital costs over the last decade.



# Our Research: Substance use in Puerto Rican breastfeeding persons






- There is limited data on substance use among breastfeeding individuals in Puerto Rico.
- Lack of research limits the effectiveness of public health education and intervention efforts.
- The role of healthcare professionals in educating caregivers about substance use risks remains unclear.
- This study aimed to:
  - Investigate substance consumption patterns among breastfeeding individuals.
  - Assess educational efforts by healthcare professionals.
  - Explore cultural factors influencing substance use behaviors in Puerto Rico.











Q3 How long have you been breastfeeding?






Q14 Did you use any of the considered substances prior to being pregnant?






Q15 Why were you consuming the substance(s) prior to being pregnant?






Q16 Did you continue using the substance(s) while pregnant?






Q17 Why were you consuming the substance(s) while pregnant?






Q18 Have you consumed any of the considered substances during the period that you have been breastfeeding?





Persons Q19 Which of the following substances have you consumed during the period that you have been breastfeeding? How frequently? 9% 26% 50% 98% Nicotine 86% 99% Opioids 99% Stimulants 1% Analgesics Hallucinogens 99% 13% 3% 3% 79% Caffeine Benzodiazepines 1% 99% 98% Sedatives Inhalants Paychiatric 94% Biweekly Anually Does not a.







#### Breastfeeding

- 50% of participants have exclusively breastfed.
- 25% of participants have breastfed for at least 1.5 years.

#### Substance use

- 76% of participants reported using at least one substance before pregnancy.
- 51% continued using substances during pregnancy.
- 70% of participants used at least one substance while breastfeeding.



The study reveals a high prevalence of substance use during pregnancy and breastfeeding, highlighting the urgency of improving education during these stages.

Although 71% of participants received information about the risks of substance use during breastfeeding, the consumption persisted.

The results emphasize the need to ensure that the information provided to this population is up-to-date, accessible, culturally adapted, and free of stigma. It is suggested to implement early interventions, including psychoeducation, psychological support, and educational programs, to promote healthy practices and the well-being of breastfeeding persons and their babies.



# Evidence-based recommendations & updated protocols







# Benefits of Breastfeeding

#### Infant

- Optimal nutrition
- Immune protection and reduced risk of developing certain diseases
- Neonatal abstinence syndrome (NAS) reduction
- Easier digestion
- Long-term health benefits

#### Breastfeeding parent

- Stronger parent-infant bond
- Faster postpartum recovery
- Weight loss
- Reduced risk of chronic diseases
- Costefectiveness and convenience



## Clinical Scenario #1

\*30-year-old patient with opioid use disorder, currently on MOUD with methadone (60mg/day): requests counseling for breastfeeding a 3-day-old infant with mild NAS (Finnegan score)

\*How would you counsel this patient?

- o Is it safe to breastfeed?
- What monitoring is required?






## **Opioid Use and Breastfeeding**

Aspect	Methadone	Buprenorphine	Other opioids (Fentanyl, Heroin)
Compatibility	Compatible (ABM Protocol 21); <3% transfer to milk	Compatible (ABM); lower risk of Neonatal Abstinence Syndrome (NAS)	Contraindicated (ABM); requires abstinence or MOUD.
Transfer	Minimal transfer to breastmilk <3%	Minimal transfer; lower NAS risk compared to methadone	High risk of harmful transfer, unsafe for breastfeeding
Risks	Potential for infant sedation; requires monitoring	Less sedation than methadone; safer for infants	Severe risks to infant; overdose potential, withdrawal, and harm
Recommendations	Adjusted doses (30- 120mg/day) safe (ASAM 2020); monitor infant for sedation	Preferred (ASAM); lower NAS risk and less sedation	Refer to treatment (SAMHSA/ASAM); use formula if active use continues



## **Opioid Use and Breastfeeding**





Finnegan Score

# Stimulants and Breastfeeding

- Cocaine and methamphetamine:
  - ABM Protocol 21: Contraindicated; high toxicity risk (seizures, hypertension).
  - SAMHSA: Chronic use needs intensive treatment; formula if no abstinence.
  - ASAM: High neonatal risk; prioritize parent stabilization.
- \*Prescribed Stimulants (e.g., methylphenidate):
  - ABM: Case-by-case (<20 mg/day viable); monitor agitation.</li>
  - ASAM: Assess with psychiatrist; minimal doses preferred.



## Clinical Scenario #2

\* 25-year-old patient uses cannabis occasionally (2-3 times/week) for anxiety, is currently breastfeeding a healthy 2-week-old. Patient is concerned this may affect the baby but worries that postpartum anxiety may worsen resulting in difficulties caring for the baby.

What advice would you give this patient?





## **Cannabis and Breastfeeding**

#### **#** THC Transfer:


- ABM Protocol 21: Detectable up to 6 days;
  cumulative risk.
- SAMHSA: Limited data, advises against due to neurodevelopment.

#### **\*** Risks:

- ABM: Cognitive/motor impact; somnolence.
- ASAM: Insufficient evidence for recreational use; suspend if active.

#### **\*** Recommendations:

ABM: Discourage; avoid breastfeeding 24 48 hours post-use if continued





## Clinical Scenario #3

This is a 28-year-old parent who drinks 1-2 glasses of wine on weekends, breastfeeding a 1-month-old with normal growth.

# How would you counsel this patient?





## **Alcohol and Breastfeeding**

#### \* Alcohol Transfer:

- ABM Protocol 21: Peak at 30-60 min; wait 90-120 min/drink.
- SAMHSA: Occasional use compatible; avoid in alcohol use disorder (AUD).

#### **\*** Risks:

- ABM: Sedation, chronic cognitive delays.
- ASAM: High doses (>2 drinks) need intervention.

#### **\*** Recommendations:

 ABM: "Pump and dump" if needed; abstinence ideal.

	STANDARD DRINK(S)	STANDARD DRINK(S)	STANDARD DRINK(S)	STANDARD DRINK(S)	5 STANDARD DRINK(S)	5 STANDARD DRINK(S)	STANDARD DRINK(S)	STANDARD DRINK(S)		
WEIGHT	HOURS : MINUTES									
90 LBS	2:50	5:40	8:30	11:20	14:10	17:00	19:51	22:41		
95 LBS	2:16	5:32	8:19	11:05	13:52	16:38	19:25	22:11		
100 LBS	2:42	5:25	8:08	10:51	13:34	16:17	19:00	21:43		
105 LBS	2:39	5:19	7:58	10:38	13:18	15:57	18:37	21:16		
110 LBS	2:36	5:12	7:49	10:25	13:01	15:38	18:14	20:50		
115 LBS	2:33	5:06	7:39	10:12	12:46	15:19	17:52	20:25		
120 LBS	2:30	5:00	7:30	10:00	12:31	15:01	17:31	20:01		
125 LBS	2:27	4:54	7:22	9:49	12:16	14:44	17:11	19:38		
130 LBS	2:24	4:49	7:13	9:38	12:03	14:27	16:52	19:16		
135 LBS	2:21	4:43	7:05	9:27	11.49	14:11	16:33	18:55		
140 LBS	2:19	4:38	6:58	9:17	11:37	13:56	16:15	18:35		
145 LBS	2:16	4:33	6:50	9:07	11:24	13:41	15:58	18:15		
150 LBS	2:14	4:29	6:13	8:58	11:12	13:27	15:41	17:56		
155 LBS	2:12	4:24	6:36	8:48	11:01	13:13	15:25	17:37		
160 LBS	2:10	4:20	6:30	8:40	10:50	13:00	15:10	17:20		
165 LBS	2:07	4:15	6:23	8:31	10:39	12:47	14:54	17:02		
170 LBS	2:05	4:11	6:17	8:23	10:28	12:34	14:40	16:46		
175 LBS	2:03	4:07	6:11	8:14	10:18	12:22	14:26	16:29		
180 LBS	2:01	4:03	6:05	8:07	10:08	12:10	14:12	16:14		
185 LBS	1:59	3:59	5:59	7:59	9:59	11:59	13:59	15:59		
190 LBS	1:58	3:56	5:54	7:52	9:50	11:48	13:46	15:44		
195 LBS	1:56	3:52	5:48	7:44	9:11	11:37	13:33	15:29		
200 LBS	1:54	3:49	5:43	7:38	9:32	11:27	13:21	15:16		
205 LBS	1:52	3:45	5:38	7:31	9:24	11:17	13:09	15:02		
205 LBS	1:52	3:45	5:38	7:31	9:24	11:17	13:09	15:02		
210 LBS	1:51	3:42	5:33	7:24	9:16	11:07	12:58	14:49		

Source: www.cdc.gov/breastfeeding/breastfeeding-special-circumstances/vaccinations-medications-drugs/alcoho



# **Tobacco and Breastfeeding**

#### Nicotine Transfer:

- ABM Protocol 21: Detectable; secondhand smoke worsens risks.
- SAMHSA: Smoking reduces milk output (250 mL/day less).

#### \* Risks:

- ABM: SIDS (2-4x risk), respiratory infections.
- ASAM: nicotine replacement compatible.

#### Recommendations:

ABM: Breastfeeding better than formula; support cessation.



# Ethical and Legal Considerations


#### Ethical Dilemmas:

- Autonomy vs. Beneficence: Balancing parental choice (e.g., breastfeeding on methadone) with infant safety (e.g., heroin use).
- Stigma: Parents with SUD face bias (e.g., "unfit"); risk of withdrawing from care.
- Equity: Unequal access to medication for addiction treatment or lactation support in marginalized communities.

#### Legal Aspects:

- Reporting: Illicit use may require notification (varies by jurisdiction).
- Confidentiality: Protect data unless imminent risk; informed consent essential.
- <u>Custody</u>: Breastfeeding may factor into child protection cases.










## Final takeaways



- The **transition to parenthood** is a key period where substance use behaviors can significantly affect infant well-being.
- Understanding SUD during pregnancy and breastfeeding is critical due to its impact on both parental and infant health.
- Public health efforts must focus on supporting breastfeeding individuals in avoiding harmful substance use.



### **Contact Information**



- \* Michelle A. Cabán-Ruiz, Ph.D.
- michelle.caban@uccaribe.edu
  - (787)798-3001; ext. 2707
- Angélica M. Fuentes-Armesto M.D, DABFMangelica.fuentes@uccaribe.edu
  - Henry X. Nieves-Díaz, M.D, DABFM
    - <u>henry.nieves@uccaribe.edu</u>





## References

- 1. Admon, L. K., Winkelman, T. N., Moniz, M. H., Davis, M. M., Heisler, M., & Dalton, V. K. (2017). Disparities in chronic conditions among women hospitalized for delivery in the United States, 2005–2014. Obstetrics & Gynecology, 130(6), 1319-1326.
- 2. American Psychiatric Association, D. S. M. T. F., & American Psychiatric Association, D. S. (2013). *Diagnostic and statistical manual of mental disorders: DSM-5* (Vol. 5, No. 5). Washington, DC: American Psychiatric Association.
- 3. Cabán-Ruiz, M., Fuentes-Armesto, A., & Nieves-Díaz, H. (2025). Substance Use in Puerto Rican Breastfeeding Mothers [Manuscript in preparation]. Addiction Medine Fellowship, Universidad Central del Caribe.
- 4. Center for Behavioral Health Statistics and Quality. (2016). 2015 National Survey on Drug Use and Health: Detailed Tables. In S. A. a. M. H. S. Administration (Ed.). Rockville, MD.
- 5. Cornish, J. L., & Prasad, A. A. (2021). Sex differences in substance use disorders: a neurobiological perspective. Frontiers in global women's health, 2, 778514.
- Degenhardt, L., Charlson, F., Ferrari, A., Santomauro, D., Erskine, H., Mantilla-Herrara, A., ... & Vos, T. (2018). The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *The Lancet Psychiatry*, 5(12), 987-1012.
- 7. Grant, B. F., Chou, S. P., Saha, T. D., Pickering, R. P., Kerridge, B. T., Ruan, W. J., ... & Hasin, D. S. (2017). Prevalence of 12-month alcohol use, high-risk drinking, and DSM-IV alcohol use disorder in the United States, 2001-2002 to 2012-2013; results from the National Epidemiologic Survey on Alcohol and Related Conditions. *IAMA psychiatry*, 74(9), 911-923.
- 8. McHugh, R. K., Votaw, V. R., Sugarman, D. E., & Greenfield, S. F. (2018). Sex and gender differences in substance use disorders. Clinical psychology review, 66, 12-23.
- 9. Reece-Stremtan, S., Marinelli, K. A., & Academy of Breastfeeding Medicine. (2023). ABM clinical protocol# 21: guidelines for breastfeeding and substance use or substance use disorder. *Breastfeeding Medicine*, 10(3), 135-141.
- 10. Reitsma, M. B., Kendrick, P. J., Ababneh, E., Abbafati, C., Abbasi-Kangevari, M., Abdoli, A., ... & Gorini, G. (2021). Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990-2019: a systematic analysis from the Global Burden of Disease Study 2019. *The Lancet*, 397(10292), 2337-2360.
- Rodríguez-Meira, C. A., Buccini, G., Azeredo, C. M., Conde, W. L., & Rinaldi, A. E. M. (2022). Evolution of breastfeeding indicators and early introduction of foods in Latin American and Caribbean countries in the decades of 1990, 2000 and 2010. International Breastfeeding Journal, 17(1), 32.
- 12. Smith, C. B., Schmidt, J., Holdsworth, E. A., Caffé, B., Brooks, O., Williams, J. E., ... & Meehan, C. L. (2024). Cannabis use, decision making, and perceptions of risk among breastfeeding individuals: the Lactation and Cannabis (LAC) Study. *Journal of Cannabis Research*, 6(1), 6.
- 13. Substance Abuse and Mental Health Services Administration. (2018). Clinical guidance for treating pregnant and parenting women with opioid use disorder and their infants. Vol HHS Publication No.(SMA) 18-5054.
- 14. Verplaetse et al., 2021 https://doi.org/10.1016/j.addbeh.2021.107055
- 15. Vesga-López O, Blanco C, Keyes K, Olfson M, Grant BF, Hasin DS. Psychiatric disorders in pregnant and postpartum women in the United States. Arch Gen Psychiatry. 2008 Jul;65(7):805-15. doi: 10.1001/archpsyc.65.7.805. PMID: 18606953; PMCID: PMC2669282.
- Volkow, N. D., & Blanco, C. (2023). Substance use disorders: a comprehensive update of classification, epidemiology, neurobiology, clinical aspects, treatment and prevention. World Psychiatry, 22(2), 203-229.
- 17. World Health Organization. (2018). *Global status report on alcohol and health 2018*. World Health Organization.

